Johnson & JohnsonRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Total: 60.4K usd_millions
| Asset | Status printed in Q2 2026 | Why it matters |
|---|---|---|
| Icotrokinra (oral IL-23) | First-line systemic plaque psoriasis launch underway; more than 10,000 patients initiated (earnings call) | Oral immunology follow-on to Tremfya |
| Imaavy / nipocalimab (wAIHA) | FDA granted Priority Review for warm autoimmune hemolytic anemia | Autoantibody-driven disease with no FDA-approved therapy at the print date |
| Rybrevant Faspro | Pivotal data in advanced head and neck cancer | Subcutaneous EGFR/MET bispecific expansion beyond NSCLC |
| Talvey + Darzalex Faspro | Earlier-line relapsed or refractory multiple myeloma data | Bispecific plus CD38 combination behind the myeloma franchise |
| Ottava robotic surgery system | Pivotal clinical study results in upper abdominal procedures; FDA de novo path previously filed | MedTech robotics, not captured in FMP product mix |
| Orthopaedics separation | Intent to separate DePuy Synthes announced October 2025; FY 2024 Orthopaedics sales about $9.2 billion | Would leave J&J focused on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision |
Total: 33.8K usd_millions